176 related articles for article (PubMed ID: 32853569)
1. Impact of Age on Surgical Outcomes for Locally Advanced Esophageal Cancer.
Farrow NE; Raman V; Jawitz OK; Voigt SL; Tong BC; Harpole DH; D'Amico TA
Ann Thorac Surg; 2021 Mar; 111(3):996-1003. PubMed ID: 32853569
[TBL] [Abstract][Full Text] [Related]
2. Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.
Raman V; Jawitz OK; Voigt SL; Farrow NE; Yang CJ; D'Amico TA; Harpole DH
Ann Thorac Surg; 2019 Dec; 108(6):1633-1639. PubMed ID: 31356800
[TBL] [Abstract][Full Text] [Related]
3. Stage III esophageal adenocarcinoma: definitive chemoradiation vs. chemoradiation plus surgery.
Schlottmann F; Strassle PD; Gaber C; Patti MG
Updates Surg; 2018 Dec; 70(4):423-426. PubMed ID: 29926306
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
[TBL] [Abstract][Full Text] [Related]
5. Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly.
Abrams JA; Buono DL; Strauss J; McBride RB; Hershman DL; Neugut AI
Cancer; 2009 Nov; 115(21):4924-33. PubMed ID: 19637343
[TBL] [Abstract][Full Text] [Related]
6. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities.
Jensen GL; Hammonds KP; Haque W
Dis Esophagus; 2023 Jan; 36(2):. PubMed ID: 35901451
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
9. Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation.
Gabriel E; Attwood K; Du W; Tuttle R; Alnaji RM; Nurkin S; Malhotra U; Hochwald SN; Kukar M
JAMA Surg; 2016 Mar; 151(3):234-45. PubMed ID: 26559488
[TBL] [Abstract][Full Text] [Related]
10. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
Franko J; Voynov G; Goldman CD
Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
[TBL] [Abstract][Full Text] [Related]
11. Surgically Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database.
Sathe TS; Resio BJ; Hoag JR; Monsalve AF; Pathak R; Blasberg JD; Mase V; Dhanasopon A; Boffa DJ
Ann Thorac Surg; 2020 Jun; 109(6):1656-1662. PubMed ID: 32109449
[TBL] [Abstract][Full Text] [Related]
12. Minimally invasive esophagectomy provides significant survival advantage compared with open or hybrid esophagectomy for patients with cancers of the esophagus and gastroesophageal junction.
Palazzo F; Rosato EL; Chaudhary A; Evans NR; Sendecki JA; Keith S; Chojnacki KA; Yeo CJ; Berger AC
J Am Coll Surg; 2015 Apr; 220(4):672-9. PubMed ID: 25667145
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.
Tiesi G; Park W; Gunder M; Rubio G; Berger M; Ardalan B; Livingstone A; Franceschi D
J Surg Res; 2017 Aug; 216():65-72. PubMed ID: 28807215
[TBL] [Abstract][Full Text] [Related]
14. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.
Marks JL; Hofstetter W; Correa AM; Mehran RJ; Rice D; Roth J; Walsh G; Vaporciyan A; Erasmus J; Chang J; Maru D; Lee JH; Lee J; Ajani JA; Swisher SG
Ann Thorac Surg; 2012 Oct; 94(4):1126-32; discussion 1132-3. PubMed ID: 22921233
[TBL] [Abstract][Full Text] [Related]
15. Consequences of Refusing Surgery for Esophageal Cancer: A National Cancer Database Analysis.
Rahouma M; Harrison S; Kamel M; Nasar A; Lee B; Port J; Altorki N; Stiles B
Ann Thorac Surg; 2018 Nov; 106(5):1476-1483. PubMed ID: 30055137
[TBL] [Abstract][Full Text] [Related]
16. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
17. Effect of time to surgery on outcomes in stage I esophageal adenocarcinoma.
Raman V; Jawitz OK; Voigt SL; Yang CJ; Wang H; Harpole DH; D'Amico TA
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1626-1635.e1. PubMed ID: 31740115
[TBL] [Abstract][Full Text] [Related]
18. Trends in Treatment of T1N0 Esophageal Cancer.
Semenkovich TR; Hudson JL; Subramanian M; Mullady DK; Meyers BF; Puri V; Kozower BD
Ann Surg; 2019 Sep; 270(3):434-443. PubMed ID: 31274653
[TBL] [Abstract][Full Text] [Related]
19. Comparison of endoscopic therapies and surgical resection in patients with early esophageal cancer: a population-based study.
Wani S; Drahos J; Cook MB; Rastogi A; Bansal A; Yen R; Sharma P; Das A
Gastrointest Endosc; 2014 Feb; 79(2):224-232.e1. PubMed ID: 24060519
[TBL] [Abstract][Full Text] [Related]
20. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer.
Shaikh T; Meyer JE; Horwitz EM
Surg Oncol Clin N Am; 2017 Jul; 26(3):405-429. PubMed ID: 28576180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
